About Almatica Pharma

Almatica Pharma, Inc., a subsidiary of Alvogen, is focused on the acquisition of mature brand Rx and OTC pharmaceutical products. Established in 2008, Almatica Pharma has a current portfolio that includes Urology and Women’s Health products with additional portfolio growth expected in 2010. Almatica’s portfolio of products currently includes:

• Macrodantin (nitrofurantoin macrocrystals capsule) for treatment of acute and reoccurring urinary tract infection
• Macrobid (nitrofurantoin monohydrate/macrocrystals capsule) for treatment of acute urinary tract infections
• Today Sponge female contraceptive

Almatica is led by an experienced brand pharmaceutical management team and our current operations consist of established systems to support all aspects of brand product management including regulatory affairs, sales, marketing, customer service, and pharmacovigilance.

The parent company of Almatica, Alvogen, is a multinational, privately owned pharmaceuticals company. Alvogen is focused on building the next-generation pharmaceuticals organization through the strategic selection of products, partners and markets, and the utilization of an effective consolidated global supply chain. Alvogen’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has first-class regulatory, development and manufacturing capabilities in Asia, Europe and North America. Alvogen's lines of business include:

• Almatica Pharma focusing on mature pharmaceutical brands
• Alvogen Inc. focusing on generic pharmaceutical products for the United States, Europe, Asia and Latin America
• Norwich Pharmaceuticals offering contract manufacturing to a diversified group of pharmaceutical companies
• Norwich Clinical Services offering outsourced pharmacovigilance, biostudies, and clinical trial programs

For additional information, visit www.alvogen.com.